Amylyx Pharmaceuticals (AMLX) CLO auto-sells 3,419 shares for taxes

Rhea-AI Filing Summary

Amylyx Pharmaceuticals Chief Legal Officer Gina Mazzariello reported an automatic sale of company stock tied to tax withholding. On February 23, 2026, she sold 3,419 shares of common stock in open-market transactions at a weighted average price of $14.1422 per share. The filing explains these shares were sold automatically to cover tax obligations from the vesting of restricted stock units, not at her discretion. After these transactions, she beneficially owned 141,274 shares of Amylyx common stock.

Insider Trade Summary

Net Seller: 3,419 shares ($48,352)

Net Sell 1 txn

Insider Mazzariello Gina

Role Chief Legal Officer

Sold 3,419 shs ($48K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,419	$14.1422	$48K

Holdings After Transaction: Common Stock — 141,274 shares (Direct)

Footnotes (1)

1. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.030 to $14.220. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mazzariello Gina

(Last) (First) (Middle)

C/O AMYLYX PHARMACEUTICALS, INC.

55 CAMBRIDGE PARKWAY, SUITE 6W

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Amylyx Pharmaceuticals, Inc. [ AMLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/23/2026		S(1)		3,419	D	$14.1422(2)	141,274	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.030 to $14.220. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

	/s/ Joshua B. Cohen, as Attorney in Fact	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Amylyx Pharmaceuticals (AMLX) report for Gina Mazzariello?

Amylyx Pharmaceuticals reported that Chief Legal Officer Gina Mazzariello automatically sold 3,419 shares of common stock. The sale occurred on February 23, 2026 to satisfy tax withholding obligations from vesting restricted stock units, rather than a discretionary open-market decision.

How many Amylyx (AMLX) shares did Gina Mazzariello sell and at what price?

Gina Mazzariello sold 3,419 Amylyx common shares at a weighted average price of $14.1422. The filing notes multiple trades between $14.030 and $14.220, with full transaction breakdowns available to SEC staff upon request for additional detail.

Why did Amylyx’s Chief Legal Officer sell 3,419 AMLX shares?

The 3,419 shares were sold automatically to cover tax withholding obligations on vesting restricted stock units. The filing specifies these sales were required for tax purposes and were not executed at the personal discretion of Chief Legal Officer Gina Mazzariello.

How many Amylyx (AMLX) shares does Gina Mazzariello hold after this Form 4 sale?

Following the reported sale, Gina Mazzariello beneficially owned 141,274 shares of Amylyx common stock. This figure reflects her remaining direct holdings after 3,419 shares were sold to satisfy tax withholding tied to the vesting of restricted stock units.

Was the Amylyx (AMLX) insider stock sale by Gina Mazzariello an open-market trade?

Yes, the transaction is coded as an open-market sale, but it served to cover tax withholding on vesting restricted stock units. The sales were automatic under this tax requirement, rather than an elective decision to trade shares on the open market.

What price range did Amylyx (AMLX) shares sell for in Gina Mazzariello’s Form 4?

The weighted average sale price was $14.1422 per share, with individual trades executed between $14.030 and $14.220. The company notes that detailed share counts at each specific price can be provided to SEC staff upon request.